Forecast

The analysts' average price target is €2.59 (+56.97%). The median is €2.59 (+56.97%).

Buy	4
Hold	3
Sell	0

News Go to news feed

Evotec share falls after €125 million convertible bond and share placement

Evotec's share lost around 9.5% by midday on Wednesday, falling to €4.60, after the company issued a €125 million convertible bond and at the same time placed existing shares. The placement served as protection for investors and weighed on the price because of expected dilution effects if the bonds are converted into shares. In addition, speculative players such as hedge funds could subscribe to the bonds and short-sell shares as a hedge, which can create additional pressure. » More on de.investing.com
Evotec slips into loss at start of year due to restructuring costs and lost license revenues

Evotec reports a Q1 revenue drop of more than 20% to just under €157m, an adjusted EBITDA of -€21.9m (previous year €3.1m) and a net loss of around €122m. Weighing on results were high restructuring costs, one-off license income in the prior year, currency effects and a weak market environment in drug discovery. CEO Christian Wojczewski calls the development not surprising, sees early signs of recovery in order intake and confirms cost reductions including the closure of several sites and up to 800 job cuts. Evotec keeps its 2026 guidance (revenue €700–780m, adjusted EBITDA €0–40m) and targets long-term revenue >€1bn and an adjusted operating margin above 20% by 2030. » More on finanzen.net
Evotec: CFO departure, activist demands IPO of Just Biologics and faster restructuring

Paul Hitchin resigns after just 14 months as chief financial officer; Claire Hinshelwood will take over the role on May 1. MAK Capital is calling for a standalone IPO of the US subsidiary Just Biologics and an accelerated pace of restructuring. Goldman Sachs also holds a significant position among shareholders. Evotec has declared 2026 the year of restructuring, but now needs to deliver concrete results to ensure the recent share-price recovery holds. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2016, Evotec ADR has already paid €0.0561 in dividends. The last payout was in January 2016.

Financials

In the last quarter, Evotec ADR had revenue of €145.85M and net profit of -€47.42M

(EUR)	Jun 2026	YoY
Revenue	145.85M	14.82%
Gross profit	-1.61M	118.69%
Net profit	-47.42M	9.07%
EBITDA	-27.13M	692.81%

Fundamentals

Metric	Value
Market capitalization	€597.89M
Number of shares	355.24M
52-week high/low	€3.69 - €1.61
Dividends	No
Beta	1.26
P/E ratio	-3.08
PEG ratio	0.04
P/B ratio	0.91
P/S ratio	0.84

Company profile

Evotec SE ist als Wirkstoffforschungs- und -entwicklungspartner für die Pharma- und Biotechnologiebranche weltweit tätig. Das Unternehmen entwickelt pharmazeutische Produkte in verschiedenen therapeutischen Bereichen wie Diabetes und Diabetes-Komplikationen, Fibrose, Infektionskrankheiten, ZNS-Erkrankungen, Onkologie, Schmerz und Entzündung, Immunologie, seltene Krankheiten, Atemwegserkrankungen und Frauengesundheit. Das Unternehmen hat Kooperationsvereinbarungen mit Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd, Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics und Takeda Pharmaceuticals. Das Unternehmen war früher unter dem Namen Evotec AG bekannt und änderte im April 2019 seinen Namen in Evotec SE. Evotec SE wurde 1993 gegründet und hat seinen Hauptsitz in Hamburg, Deutschland.